Stay updated with breaking news from Its alzheimer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's Study tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Exscientia. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive royalties on net sales of any marketed drug products resulting from the collaboration. The biotech industry is increasingly using AI to deploy targeted drug molecules to test the efficacy of drugs to tackle illnesses ranging from cancer to heart disease. Headquarters of Bristol-Myers Squibb Germany in Munich, Germany. Andrew Hopkins, CEO of Exscientia, commented, “…this expanded collaboration …speaks to the strength and promise of Exscientia’s AI technologies and drug discovery expertise. We’re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients.” ....